The issue with CFTR modulators is that they don’t work on every CF case. However, the company developed its competitive edge ...
The task ahead of Vertex now is to migrate patients already on Trikafta to the new drug. That is supported by data from the ...
Throughout Gunnar Esiason's journey with cystic fibrosis, the sport of hockey has always been huge part of his family. See ...
The FDA's nod is based on late-stage data, which show that treatment with VRTX's Alyftrek enhances patient benefit compared ...
Vertex Pharmaceuticals Inc. notched two FDA victories late Friday for its cystic fibrosis medicines, increasing the number of ...
Alyftrek is approved as a new treatment for cystic fibrosis, while the FDA expanded the label for Trikafta to include additional genetic mutations.
The new combination, dubbed Alyftrek, is designed to improve on the Trikafta, a product that generated sales of $8.9 billion ...
As Vertex Pharmaceuticals reels from a painful trial readout for its pain candidate suzetrigine, the Boston biotech has ...
Vertex has won two cystic fibrosis approvals from the FDA, but the agency included high-level safety warnings.
US drugmaker Vertex Pharmaceuticals’ shares were unmoved on Friday, despite receiving two new regulatory authorizations.
The US Food and Drug Administration has approved Alyftrek, a once-daily oral combination of vanzacaftor, tezacaftor, and ...
5d
Different genetic mutations cause different problems with this particular protein -- so CFTR modulators generally don't work ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback